Clinical Trials Arena’s Post

FEATURE - 2023 in review: Cancer vaccines dose up on advances with tailored approaches As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital. - https://lnkd.in/d3pv5A6h #cancer #cancervaccine #oncology #personalizedmedicine

Cancer Vaccine Shows Promise in Patients with Pancreatic, Colon Cancer A recent #study, co-led by #researchers at Memorial Sloan Kettering #Cancer Center, reveals encouraging early results for an off-the-shelf cancer vaccine, ELI-002 2P, designed for patients with pancreatic or colorectal cancer carrying specific KRAS mutations. The #vaccine, tested in a Phase I trial with 25 high-risk patients, was deemed safe and demonstrated a significant immune response, activating T cells targeting KRAS-mutated cancer cells. Notably, 84% of patients exhibited the desired immune response, leading to reduced circulating #tumor #DNA and, in some cases, complete absence. The findings suggest potential benefits in delaying cancer recurrence for responsive patients. #Ariti #health #healthcare #pharmaceuticals #people #peoplefirst #patientcare #medical #medicaldevice Read more : https://lnkd.in/dJRjPz3n

The first patient has received a personalized vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad. The plan is that thousands of patients in England will gain access to personalized cancer vaccine trials through the new matchmaking service for patients and drug developers. The vaccines being evaluated in the colorectal cancer trial are based on mRNA—the same technology used for the Pfizer-BioNTech COVID-19 vaccine. A patient’s tumor is analyzed to identify specific mutations and an experimental individualized cancer vaccine is created. Learn more from Inside Precision Medicine: https://bit.ly/3VEJf0B | #PrecisionMedicine #mRNA #ClinicalTrials #DrugDevelopment #CancerVaccine

🌟 Curious about cancer vaccines? Check out this article from Nature for a quick read about different approaches and potential of therapeutic cancer vaccines, accompanied by some very nice schematics 🔬

The deployment of personalised cancer vaccines relies on the successful combination of multiple approaches, such as NGS, AI, GMP manufacturing and diagnostics. In our latest Insight article, Elena and I explore the challenges and opportunities in shaping a world where personalised cancer vaccines are for everyone. Read more: https://lnkd.in/eu8BnBQS

Last week I predicted (LinkedIn translation 🙄 🤡: Reposted) how the pandemic had dramatically advanced mRNA vaccines in the fight against cancer... More good news coming out of #ASCO today related to vaccines against melanoma in combination with immunotherapies. Melanoma affects over 150,000 people globally each year. The vaccine, known as mRNA-4157 (V940), is tailored to each patient using DNA sequencing and artificial intelligence, aiming to prevent the cancer from returning. It has shown to halve the risk of death or disease recurrence in patients. After three years, those who received the vaccine had a 49% lower risk of these outcomes. Highlighting the potential of therapeutic cancer vaccines in combination with immunotherapies to greatly improve patient outcomes.

Cancer vaccines are taking off! Merck and Moderna’s personalised mRNA cancer vaccine, mRNA-4157/V940, combined with Keytruda, delivers a breakthrough in melanoma treatment. This combination therapy reduces the risk of recurrence or death by 44% compared to Keytruda alone, showcasing a significant advancement in cancer immunotherapy. The success of this trial highlights the potential of mRNA technology beyond COVID-19 vaccines and sets the stage for further expansion into other cancer types. Read the full story here: https://lnkd.in/ePBAtWCu #CancerVaccines #mRNA #CancerResearch

Click here to read about the many mRNA updates from this past week! Sneak Peak: 👨🔬 Moderna embarked on a late-stage trial of how the vaccine technology works against melanoma when administered in combination with Merck's immunotherapy Keytruda. 👩🔬 BioNTech SE has mRNA vaccines against melanoma and head and neck cancers in phase 2 trials. 👨🔬 The University of Florida scientists used mRNA technology to attack glioblastoma in a small early-stage clinical trial. 👩🔬 The University of Cincinnati is testing a therapeutic vaccine against pancreatic cancer. More #Science Below 🔬 💉 😷 https://lnkd.in/ezsgBymi #precisionmedicine #medicine #businessintelligence #mRNA #healthcare

Some fascinating insight about the potential role of neoantigens in a future where personalised cancer vaccines are ubiquitous. Given the manufacturing challenge, I'm interested to see what can be reapplied from Cellular Origins' scalable manufacture of cell and gene therapy.

Exciting news in the world of cancer research! Clinical trials in 2023 suggest that a transformative technology may be approaching. An experimental vaccine, targeting unique cancer proteins called neoantigens, combined with an immunotherapy drug, reduced melanoma recurrence risk by 44%. This promising result from a phase 2 trial has led to a larger phase 3 trial underway. The vaccine platform is similar to Moderna's COVID-19 vaccine, offering hope for a breakthrough in cancer treatment. #cancerresearch #clinicaltrials #immunotherapy #vaccine #cancertreatment https://lnkd.in/gADBHvm9